Clinical Trial Update: Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the safety, tolerability, and immunogenicity of MVA.HTI and ChAdOx1.HTI with vesatolimod in HIV-1 positive patients is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids

Drugs mentioned

• ChAdOx1.HTI
• MVA.HTI
• Vesatolimod (vesatolimod)

Snippet

Sponsor: Aelix Therapeutics | Conditions: HIV/AIDS | Phase 2 | Status: COMPLETED